SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (22494)6/18/1998 5:52:00 PM
From: Skeeter Bug  Respond to of 32384
 
henry, i thought this source was reliable ;-) well, hopefully next month. may buy back in soon...



To: Henry Niman who wrote (22494)6/18/1998 9:38:00 PM
From: Machaon  Read Replies (1) | Respond to of 32384
 
There's about 316 new drugs being developed to fight cancer.

That is a LOT of competition for LGND. Perhaps this is why the market isn't willing to give LGND a higher value than about $500 million.

You've quoted an analyst that predicts about $14 per share in 2006. But, with over 300 new cancer drugs, being developed, some of which will become big winners, doesn't that diminish LGND's future earnings capabilities?

Regards, Bob


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News